Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB3 (Trastuzumab Biosimilar) with Ramucirumab and Paclitaxel in HER2+ Metastatic Gastric Cancer
NCT03766607Phase 2Withdrawn
- Sponsor
- Korean South West Oncology Group
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab-dttb in gastric cancer (GC), sponsored by Korean South West Oncology Group. Planned start Sep 2019; status: withdrawn.
02
Drugs
trastuzumab-dttb
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03766607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766607.